FDA Advisory Committee Backs Merck's Keytruda for NMIBC

12/17/19

The FDA's Oncologic Drugs Advisory Committee voted 9-4 that the benefits outweigh the risks of Merck's (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.